Post-Traumatic Stress Disorder (PTSD) is becoming a very common presentation in behavioral health as well as primary care. Many traditional medications, once used to treat PTSD, are becoming refractory to treatment. Practitioners and scientists are now looking for new and innovative ways to treat this condition. However, the efficacy of EMDR compared to hallucinogen use is unclear. The National Institute of Health described PTSD as a growing epidemic, affecting approximately 7.7 million American adults. Statistics show that PTSD can occur at any age, and often correlates with increased depression, substance abuse, and anxiety disorders. The condition may cause emotional numbness, anhedonia, and anergia. This can drive up health costs, decrease work production, and have a detrimental effect on families and marriages. Current treatments include anti-depressants, anti-hypertensives, anti-convulsants, antipsychotics, and benzodiazepines. More recent treatments include the combination of medications as well as Eye Movement Desensitization and Processing (EMDR) (Friedman & Bernardy, 2017).
"Hallucinogens Versus EMDR in the Treatment of PTSD,"
Lynchburg Journal of Medical Science: Vol. 1
, Article 22.
Available at: https://digitalshowcase.lynchburg.edu/dmscjournal/vol1/iss2/22
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.